Kura Oncology Net Income
| KURA Stock | USD 7.84 0.07 0.90% |
As of the 10th of February, Kura Oncology secures the Mean Deviation of 2.91, risk adjusted performance of (0.05), and Standard Deviation of 3.88. Kura Oncology technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices.
Kura Oncology Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.3986 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -156.6 M | -148.8 M | |
| Net Loss | -156.6 M | -148.8 M | |
| Net Loss | -122.3 M | -116.1 M | |
| Net Loss | (2.32) | (2.44) | |
| Net Income Per E B T | 0.91 | 0.81 |
Kura | Net Income | Build AI portfolio with Kura Stock |
Analyzing Kura Oncology's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Kura Oncology's current valuation and future prospects.
Latest Kura Oncology's Net Income Growth Pattern
Below is the plot of the Net Income of Kura Oncology over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Kura Oncology financial statement analysis. It represents the amount of money remaining after all of Kura Oncology operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Kura Oncology's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kura Oncology's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (173.98 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Kura Net Income Regression Statistics
| Arithmetic Mean | (71,071,443) | |
| Coefficient Of Variation | (91.82) | |
| Mean Deviation | 57,692,360 | |
| Median | (60,447,000) | |
| Standard Deviation | 65,258,638 | |
| Sample Variance | 4258.7T | |
| Range | 174M | |
| R-Value | (0.96) | |
| Mean Square Error | 347.2T | |
| R-Squared | 0.92 | |
| Slope | (12,419,441) | |
| Total Sum of Squares | 68139T |
Kura Net Income History
Other Fundumenentals of Kura Oncology
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Kura Oncology Net Income component correlations
Kura Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Kura Oncology is extremely important. It helps to project a fair market value of Kura Stock properly, considering its historical fundamentals such as Net Income. Since Kura Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kura Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kura Oncology's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. Expected growth trajectory for Kura significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Kura Oncology assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Kura Oncology requires distinguishing between market price and book value, where the latter reflects Kura's accounting equity. The concept of intrinsic value - what Kura Oncology's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Kura Oncology's price substantially above or below its fundamental value.
Understanding that Kura Oncology's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Kura Oncology represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Kura Oncology's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Kura Oncology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Kura Oncology's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Kura Oncology.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Kura Oncology on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Kura Oncology or generate 0.0% return on investment in Kura Oncology over 90 days. Kura Oncology is related to or competes with GeoVax Labs, BioLineRx, Tharimmune, Ainos, and Lipocine. Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the U... More
Kura Oncology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Kura Oncology's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Kura Oncology upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.1) | |||
| Maximum Drawdown | 22.83 | |||
| Value At Risk | (5.77) | |||
| Potential Upside | 5.01 |
Kura Oncology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kura Oncology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Kura Oncology's standard deviation. In reality, there are many statistical measures that can use Kura Oncology historical prices to predict the future Kura Oncology's volatility.| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.39) | |||
| Total Risk Alpha | (0.70) | |||
| Treynor Ratio | (0.26) |
Kura Oncology February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.25) | |||
| Mean Deviation | 2.91 | |||
| Coefficient Of Variation | (1,358) | |||
| Standard Deviation | 3.88 | |||
| Variance | 15.04 | |||
| Information Ratio | (0.1) | |||
| Jensen Alpha | (0.39) | |||
| Total Risk Alpha | (0.70) | |||
| Treynor Ratio | (0.26) | |||
| Maximum Drawdown | 22.83 | |||
| Value At Risk | (5.77) | |||
| Potential Upside | 5.01 | |||
| Skewness | 0.6616 | |||
| Kurtosis | 2.29 |
Kura Oncology Backtested Returns
Kura Oncology has Sharpe Ratio of -0.1, which conveys that the firm had a -0.1 % return per unit of risk over the last 3 months. Kura Oncology exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Kura Oncology's Mean Deviation of 2.91, standard deviation of 3.88, and Risk Adjusted Performance of (0.05) to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 1.12, which conveys a somewhat significant risk relative to the market. Kura Oncology returns are very sensitive to returns on the market. As the market goes up or down, Kura Oncology is expected to follow. At this point, Kura Oncology has a negative expected return of -0.41%. Please make sure to verify Kura Oncology's skewness, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Kura Oncology performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.34 |
Below average predictability
Kura Oncology has below average predictability. Overlapping area represents the amount of predictability between Kura Oncology time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Kura Oncology price movement. The serial correlation of 0.34 indicates that nearly 34.0% of current Kura Oncology price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.34 | |
| Spearman Rank Test | 0.32 | |
| Residual Average | 0.0 | |
| Price Variance | 0.71 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Kura Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Kura Oncology reported net income of (173.98 Million). This is 150.98% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 130.47% higher than that of the company.
Kura Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kura Oncology's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kura Oncology could also be used in its relative valuation, which is a method of valuing Kura Oncology by comparing valuation metrics of similar companies.Kura Oncology is currently under evaluation in net income category among its peers.
Kura Oncology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Kura Oncology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Kura Oncology's managers, analysts, and investors.Environmental | Governance | Social |
Kura Oncology Institutional Holders
Institutional Holdings refers to the ownership stake in Kura Oncology that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Kura Oncology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Kura Oncology's value.| Shares | Qube Research & Technologies | 2025-06-30 | 1.9 M | Dimensional Fund Advisors, Inc. | 2025-06-30 | 1.2 M | Jacobs Levy Equity Management, Inc. | 2025-06-30 | 1.1 M | Algert Global Llc | 2025-06-30 | 1.1 M | Renaissance Technologies Corp | 2025-06-30 | 1.1 M | Alethea Capital Management, Llc | 2025-06-30 | 949.3 K | Aqr Capital Management Llc | 2025-06-30 | 941.7 K | Goldman Sachs Group Inc | 2025-06-30 | 933.7 K | Assenagon Asset Management Sa | 2025-06-30 | 919.1 K | Blackrock Inc | 2025-06-30 | 9.5 M | Suvretta Capital Management, Llc | 2025-06-30 | 8.1 M |
Kura Fundamentals
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (2.08) % | ||||
| Operating Margin | (3.86) % | ||||
| Current Valuation | 145.49 M | ||||
| Shares Outstanding | 87.02 M | ||||
| Shares Owned By Insiders | 2.14 % | ||||
| Shares Owned By Institutions | 99.25 % | ||||
| Number Of Shares Shorted | 12.31 M | ||||
| Price To Earning | (9.03) X | ||||
| Price To Book | 2.79 X | ||||
| Price To Sales | 6.50 X | ||||
| Revenue | 53.88 M | ||||
| Gross Profit | (120.28 M) | ||||
| EBITDA | (169.5 M) | ||||
| Net Income | (173.98 M) | ||||
| Cash And Equivalents | 450.26 M | ||||
| Cash Per Share | 6.73 X | ||||
| Total Debt | 16.59 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 25.73 X | ||||
| Book Value Per Share | 2.79 X | ||||
| Cash Flow From Operations | 134.32 M | ||||
| Short Ratio | 7.53 X | ||||
| Earnings Per Share | (2.48) X | ||||
| Target Price | 32.45 | ||||
| Number Of Employees | 192 | ||||
| Beta | 0.24 | ||||
| Market Capitalization | 676.13 M | ||||
| Total Asset | 760.16 M | ||||
| Retained Earnings | (895.42 M) | ||||
| Working Capital | 666.12 M | ||||
| Current Asset | 86.87 M | ||||
| Current Liabilities | 5.05 M | ||||
| Net Asset | 760.16 M |
About Kura Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kura Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kura Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kura Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kura Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kura Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kura Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kura Oncology Stock:Check out For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. Expected growth trajectory for Kura significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Kura Oncology assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Kura Oncology requires distinguishing between market price and book value, where the latter reflects Kura's accounting equity. The concept of intrinsic value - what Kura Oncology's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Kura Oncology's price substantially above or below its fundamental value.
Understanding that Kura Oncology's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Kura Oncology represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Kura Oncology's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.